IVAC: Intravenous Acetaminophen for Craniotomy Patients
Study Details
Study Description
Brief Summary
Adding intraoperative IV acetaminophen, in addition to standard analgesics, will decrease opioid requirements over the first 12 hours of postoperative recovery following craniotomy. Opioids exacerbate symptoms of nausea and vomiting. Reducing postoperative opioid use hopefully will reduce incidence of nausea and vomiting in patients after craniotomy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Acetaminophen Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later. |
Drug: Acetaminophen
1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
|
No Intervention: No acetaminophen Patients will receive standard of care with no intraoperative doses of acetaminophen. |
Outcome Measures
Primary Outcome Measures
- Total narcotic dose administered over the first 12 hours of postoperative recovery. [12 hours]
Intensive care nurses will ask subject about pain and nausea every 15 minutes for the first two hours immediately after surgery and then every hour afterward for up to 12 hours. Nurses will record subject response and opioid doses given.
Secondary Outcome Measures
- Incidence of nausea during postoperative recovery [12 hours]
- Incidence of vomiting during postoperative recovery [12 hours]
- Severity of nausea during postoperative recovery [12 hours]
- Severity of vomiting during postoperative recovery [12 hours]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
At least 18 years of age
-
Weigh at least 50 kg (110.23 lbs)
-
Undergoing open, elective intracranial procedure for
-
tumor resection
-
aneurysm clipping
-
revascularization
-
Have an ASA (American Society of Anesthesiologists) physical status of 1, 2, 3, or 4
-
Able to provide written informed consent
Exclusion Criteria:
-
Significant medical disease, laboratory abnormality, or condition that, in the opinion of the investigator, would compromise patient welfare or would otherwise contraindicate study participation
-
Unable to communicate symptoms
-
Current daily opioid use (>40 mg morphine equivalent)
-
Tramadol use
-
Treated with MAO (monoamine oxidase inhibitors) inhibitors within 10 days of surgery
-
Treated with any amount of acetaminophen within 8 hours of anesthesia for surgery
-
Allergic or hypersensitive to acetaminophen or any contraindications per manufacturer's guidelines
-
Pregnancy
-
Impaired liver function
-
Participation in interventional clinical study within the last 30 days
-
Known or suspected history of alcohol or drug abuse
-
Surgery for resection of acoustic neuroma
-
Transphenoidal tumor resection
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Swedish Medical Center Cherry Hill Campus | Seattle | Washington | United States | 98122 |
Sponsors and Collaborators
- Swedish Medical Center
- Mallinckrodt
Investigators
- Principal Investigator: Arthur Lam, MD, FRCPC, Swedish Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IVAC
- 20111619